¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Retinoid X Receptor gamma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • receptor cell
    ¼ö¿ëü¼¼Æ÷
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò
  • receptor gradient
    ¼ö¿ë´Ü¹é±â¿ï±â, ¼ö¿ë´Ü¹é°æ»ç, ¼ö¿ëü°æ»ç
  • receptor imaging
    1. ¼ö¿ëü¿µ»ó 2. ¼ö¿ëü¿µ»óÈ­
  • receptor internalization
    ¼ö¿ëü³»ÀçÈ­
  • receptor potential
    ¼ö¿ëüÀüÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • receptor stimulant
    ¼ö¿ëüÀÚ±ØÁ¦
  • receptor supersensitivity
    ¼ö¿ëüÃʹΰ¨¼º
  • receptor-ligand interaction
    ¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
  • spare receptor
    ¿©ºÐ¼ö¿ëü
  • scavenger receptor
    û¼ÒÁ¦¼ö¿ëü
  • stretch receptor
    »¸Ä§¼ö¿ë±â, ½ÅÀå¼ö¿ë±â
  • sensory receptor
    °¨°¢¼ö¿ë±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÀ°Á¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü
  • receptor potential
    °¨¼ö±âÀüÀ§, °¨¼ö±âÀü¾Ð, ¼ö¿ëüÀü¾Ð
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • receptor site
    ¼ö¿ëüºÎÀ§
  • receptor stimulant
    ¼ö¿ëüÀÚ±ØÁ¦
  • receptor supersensitivity
    ¼ö¿ëüÃʹΰ¨¼º
  • sensory receptor
    °¨°¢¼ö¿ëü
  • silent receptor
    ¹«¹ÝÀÀ¼ö¿ëü
  • spare receptor
    ¿©ºÐ¼ö¿ëü
  • stretch receptor
    »¸Ä§¼ö¿ëü, ½ÅÀå¼ö¿ëü
  • T cell antigen receptor
    Ƽ¼¼Æ÷Ç׿ø¼ö¿ëü
  • tactile receptor
    Ã˰¢¼ö¿ëü
  • taste receptor
    ¹Ì°¢¼ö¿ëü
  • tension receptor
    Àå·Â¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • progesterone receptor
    ÇÁ·Î°Ô½ºÅ×·Ð(ÇÁ·ÎÁ¦½ºÅ×·Ð)¼ö¿ëü(¡­â¥é»ô÷)
  • receptor
    ¼ö¿ë±â
  • receptor amblyopia
    ¼ö¿ë±â¾à½Ã
  • receptor assay
    ¼ö¿ëÃ¼ÃøÁ¤
  • receptor autoradiography
    ¼ö¿ëü ÀÚ±â¹æ»ç¼±ÃÔ¿µ¼ú
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor blockade
    ¼ö¿ëüÂ÷´Ü
  • receptor blocking agent
    ¼ö¿ëüÂ÷´Ü<ºÀ¼â>Á¦.
  • receptor cell
    ¼ö¿ëü ¼¼Æ÷
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò(¡­÷òÎÕý£áÈ).
  • receptor gradient
    ¼ö¿ëü°æ»ç.
  • receptor hypothesis
    ¼ö¿ëü°¡¼³
  • receptor imaging
    ¼ö¿ëü¿µ»ó(È­)
  • receptor organ
    ¼ö¿ë±â°ü(áôé»Ðïί).
  • receptor potential
    ¼ö¿ë±âÀüÀ§.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • cell growth,ligand receptor binding
    ¸®°£µå¼ö¿ë±â°áÇÕ (¡­áôé»ÐïÌ¿ùê)
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°(ÀÛµ¿)¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • cold receptor
    ³Ã°¢¼ö¿ëü(Ò²ÊÆáôé»ô÷)(¼ö¿ë±â, °¨¼ö±â)
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • complement receptor 1
    º¸Ã¼ ¼ö¿ëü 1
  • complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • corpuscular receptor
    ¼Òü ¼ö¿ëü
  • distance receptor
    °Å¸®¼ö¿ë±â.
  • distance receptor
    °Å¸®(Ëå×î)¼ö¿ë±â(áôé»Ðï).
  • dominant receptor
    ¿ì¼º¼ö¿ëü.
  • dominant receptor
    ¿ì¼º¼ö¿ëü(éÐàõáôé»ô÷).
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
GCGR glucagon receptor; glucocorticoid receptor
INSRR insulin receptor-related receptor
IRR insulin receptor-related receptor; intrarenal reflux
IRS immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub...
GABA Gamma-Amino-Butyric Acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
NP gamma Neuropeptide gamma
PPAR gamma Peroxisome-proliferator-activated receptors gamma
PLC gamma Phospholipase C gamma
PLC-gamma 1 Phospholipase C gamma 1
PKC gamma Protein kinase C gamma
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
cystathionine gamma-lyase <enzyme> A multifunctional pyridoxal phosphate enzyme. In the final step in the biosynthesis of cysteine it catalyses the cleavage of cystathionine to yield cysteine, ammonia, and 2-ketobutyrate.
Chemical name: L-Cystathionine cysteine-lyase (deaminating)
Registry number: EC 4.4.1.1
(12 Dec 1998)
cystathionine gamma-synthase o-succinylhomoserine (thiol)-lyase
protein-glutamine gamma-glutamyltransferase <enzyme> An enzyme that catalyses the reaction of protein glutamine and an alkylamine to yield protein n(5)-alkylglutamine and ammonia. The gamma-carboxamide groups of peptide-bound glutamine residues act as acyl donors, and the 6-amino groups of protein- and peptide-bound lysine residues act as acceptors, to give intra- and inter-molecular n(6)-(5-glutamyl)lysine crosslinks. In the epidermis these cross-linked proteins are involved in the formation of the cornified envelope of the stratum corneum cells. In the plasma, the transglutaminase is called factor xiiia, the activated form of factor xiii. The crosslinking results in the stabilization of the fibrin clot.
Pharmacological action: coagulants.
Chemical name: Protein-glutamine:amine gamma-glutamyltransferase
Registry number: EC 2.3.2.13
(12 Dec 1998)
homocysteine cystathionine gamma-synthase <enzyme> Homocysteine and cystein yield cystathionine and h2s
Registry number: EC 4.4.-
Synonym: hccg-s
(26 Jun 1999)
human gamma globulin A preparation of the proteins of liquid human plasma, containing the antibodies of normal adults; it is obtained from pooled liquid human plasma from a number of donors and may be prepared by precipitation with organic solvents under controlled conditions of pH, ionic strength, and temperature.
Synonym: human normal immunoglobulin.
(05 Mar 2000)
spectrometry, gamma Determination of the energy distribution of gamma rays emitted by nuclei.
(12 Dec 1998)
N(epsilon)-(gamma-glutamyl)lysine hydrolase <enzyme> Enzyme which is capable of directly hydrolyzing the cross-linked isopeptide into amino acids
Registry number: EC 3.4.99.-
Synonym: n(epsilon)-(gamma-glutamyl)lysine peptidase, ggl peptidase
(26 Jun 1999)
immunoglobulins, gamma-chain Heavy chains found in the fab and fc fragments of IgG and having a molecular weight of approximately 51 kD. They contain about 450 amino acid residues arranged in four domains and an oligosaccharide component covalently bound to the fc fragment. The gamma chains of the four IgG subgroups are not identical, but resemble each other more closely than the heavy chains of a different immunoglobulin.
(12 Dec 1998)
interferon-gamma <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
kanamycin - alpha-hydroxy-gamma-aminobutyl acylase <enzyme> Transforms kanamycin into amikacin
Registry number: EC 2.3.1.-
Synonym: alpha-hydroxy-gamma-aminobutyl acylase, haba acylase
(26 Jun 1999)
l-gulono-gamma-lactone The immediate precursor of ascorbic acid in those animals capable of ascorbic acid biosynthesis.
Synonym: dihydroascorbic acid, l-gulono-gamma-lactone.
L-gulonolactone oxidase, the enzyme catalyzing the conversion of l-gulonolactone and O2 to H2O2 and l-xylo-hexulonolactone, a precursor of ascorbic acid; absent in primates.
(05 Mar 2000)
L-methionine gamma-lyase <enzyme> Pharmacological action: antimetabolites, antineoplastic
Registry number: EC 4.4.1.11
Synonym: l-methionine alpha-deamino gamma-mercaptomethane-lyase, methionine dethiomethylase, l-methioninase, methioninase
(26 Jun 1999)
acetylcholine receptor antibodies <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream.
Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission.
Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy.
AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis.
AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis.
Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis.
Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued.
Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears.
(29 Dec 1997)
amino acid receptor <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor.
(18 Nov 1997)
AMPA receptor <cell biology> Glutamate operated ion channel.
See: excitatory amino acid receptor channels.
(05 Feb 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á